单献血者单采血小板浓缩物中高迁移率群盒1 （HMGB1）水平与献血者年龄、性别和ABO血型的关系

IF 1.8 4区医学 Q3 HEMATOLOGY

Vox Sanguinis Pub Date : 2025-04-22 DOI:10.1111/vox.70033

Marco Heestermans, Charles-Antoine Arthaud, Amelie Prier, Marie-Ange Eyraud, Hind Hamzeh-Cognasse, Fabrice Cognasse, Anne-Claire Duchez

{"title":"单献血者单采血小板浓缩物中高迁移率群盒1 （HMGB1）水平与献血者年龄、性别和ABO血型的关系","authors":"Marco Heestermans, Charles-Antoine Arthaud, Amelie Prier, Marie-Ange Eyraud, Hind Hamzeh-Cognasse, Fabrice Cognasse, Anne-Claire Duchez","doi":"10.1111/vox.70033","DOIUrl":null,"url":null,"abstract":"Background and objectives: High mobility group box 1 (HMGB1) is a nuclear protein expressed by various cell types and recognized as a damage-associated molecular pattern (DAMP). DAMPs play a pivotal role in driving inflammatory responses. Platelet-derived HMGB1 has been associated with severe adverse reactions following platelet concentrate transfusions, underscoring its clinical relevance. This study investigated whether HMGB1 levels in single-donor apheresis platelet concentrates (SDA-PCs) are influenced by routinely documented donor characteristics, such as age, sex and ABO blood group.Materials and methods: We analysed HMGB1 levels in 190 unpaired SDA-PC units. Donor characteristics, that is, age, sex and ABO blood group were obtained from routine records and examined for associations with HMGB1 levels.Results: HMGB1 levels showed no significant correlation with donor age or ABO blood group. However, levels were modestly lower in SDA-PC units derived from female donors compared to male donors.Conclusion: These findings reveal donor-specific variability in HMGB1 levels, particularly regarding donor sex, and underscore the need to systematically document donor demographic and biological characteristics during blood donation. Such data could enhance our understanding of donor-related factors influencing transfusion outcomes.","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association of high mobility group box 1 (HMGB1) levels with donor's age, sex and ABO blood group in single-donor apheresis platelet concentrates.\",\"authors\":\"Marco Heestermans, Charles-Antoine Arthaud, Amelie Prier, Marie-Ange Eyraud, Hind Hamzeh-Cognasse, Fabrice Cognasse, Anne-Claire Duchez\",\"doi\":\"10.1111/vox.70033\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background and objectives: High mobility group box 1 (HMGB1) is a nuclear protein expressed by various cell types and recognized as a damage-associated molecular pattern (DAMP). DAMPs play a pivotal role in driving inflammatory responses. Platelet-derived HMGB1 has been associated with severe adverse reactions following platelet concentrate transfusions, underscoring its clinical relevance. This study investigated whether HMGB1 levels in single-donor apheresis platelet concentrates (SDA-PCs) are influenced by routinely documented donor characteristics, such as age, sex and ABO blood group.Materials and methods: We analysed HMGB1 levels in 190 unpaired SDA-PC units. Donor characteristics, that is, age, sex and ABO blood group were obtained from routine records and examined for associations with HMGB1 levels.Results: HMGB1 levels showed no significant correlation with donor age or ABO blood group. However, levels were modestly lower in SDA-PC units derived from female donors compared to male donors.Conclusion: These findings reveal donor-specific variability in HMGB1 levels, particularly regarding donor sex, and underscore the need to systematically document donor demographic and biological characteristics during blood donation. Such data could enhance our understanding of donor-related factors influencing transfusion outcomes.\",\"PeriodicalId\":23631,\"journal\":{\"name\":\"Vox Sanguinis\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vox Sanguinis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/vox.70033\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70033","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景与目的：HMGB1 （High mobility group box 1）是多种细胞类型表达的核蛋白，被认为是一种损伤相关分子模式（DAMP）。DAMPs在驱动炎症反应中起着关键作用。血小板来源的HMGB1与血小板浓缩输注后的严重不良反应有关，强调了其临床相关性。本研究调查了单供者单采血小板浓缩物（SDA-PCs）中HMGB1水平是否受到常规记录的供者特征（如年龄、性别和ABO血型）的影响。材料和方法：我们分析了190个未配对的SDA-PC单元的HMGB1水平。从常规记录中获得供体特征，即年龄、性别和ABO血型，并检查其与HMGB1水平的关系。结果：HMGB1水平与供者年龄、ABO血型无显著相关性。然而，与男性供者相比，来自女性供者的SDA-PC单位的水平略低。结论：这些发现揭示了HMGB1水平的献血者特异性差异，特别是在献血者性别方面，并强调了在献血过程中系统记录献血者人口统计学和生物学特征的必要性。这些数据可以增强我们对影响输血结果的供者相关因素的理解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Association of high mobility group box 1 (HMGB1) levels with donor's age, sex and ABO blood group in single-donor apheresis platelet concentrates.

Background and objectives: High mobility group box 1 (HMGB1) is a nuclear protein expressed by various cell types and recognized as a damage-associated molecular pattern (DAMP). DAMPs play a pivotal role in driving inflammatory responses. Platelet-derived HMGB1 has been associated with severe adverse reactions following platelet concentrate transfusions, underscoring its clinical relevance. This study investigated whether HMGB1 levels in single-donor apheresis platelet concentrates (SDA-PCs) are influenced by routinely documented donor characteristics, such as age, sex and ABO blood group.

Materials and methods: We analysed HMGB1 levels in 190 unpaired SDA-PC units. Donor characteristics, that is, age, sex and ABO blood group were obtained from routine records and examined for associations with HMGB1 levels.

Results: HMGB1 levels showed no significant correlation with donor age or ABO blood group. However, levels were modestly lower in SDA-PC units derived from female donors compared to male donors.

Conclusion: These findings reveal donor-specific variability in HMGB1 levels, particularly regarding donor sex, and underscore the need to systematically document donor demographic and biological characteristics during blood donation. Such data could enhance our understanding of donor-related factors influencing transfusion outcomes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Vox Sanguinis 医学-血液学

CiteScore

4.40

自引率

11.10%

发文量

156

审稿时长

6-12 weeks

期刊介绍： Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections: 1) Transfusion - Transmitted Disease and its Prevention: Identification and epidemiology of infectious agents transmissible by blood; Bacterial contamination of blood components; Donor recruitment and selection methods; Pathogen inactivation. 2) Blood Component Collection and Production: Blood collection methods and devices (including apheresis); Plasma fractionation techniques and plasma derivatives; Preparation of labile blood components; Inventory management; Hematopoietic progenitor cell collection and storage; Collection and storage of tissues; Quality management and good manufacturing practice; Automation and information technology. 3) Transfusion Medicine and New Therapies: Transfusion thresholds and audits; Haemovigilance; Clinical trials regarding appropriate haemotherapy; Non-infectious adverse affects of transfusion; Therapeutic apheresis; Support of transplant patients; Gene therapy and immunotherapy. 4) Immunohaematology and Immunogenetics: Autoimmunity in haematology; Alloimmunity of blood; Pre-transfusion testing; Immunodiagnostics; Immunobiology; Complement in immunohaematology; Blood typing reagents; Genetic markers of blood cells and serum proteins: polymorphisms and function; Genetic markers and disease; Parentage testing and forensic immunohaematology. 5) Cellular Therapy: Cell-based therapies; Stem cell sources; Stem cell processing and storage; Stem cell products; Stem cell plasticity; Regenerative medicine with cells; Cellular immunotherapy; Molecular therapy; Gene therapy.